Psoriatic Arthritis News and Research

RSS

Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

Psoriasis drug also effective at reducing aortic inflammation

Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.

18 Feb 2018

Researchers discover link between rheumatoid arthritis and bacteria in milk

A strain of bacteria commonly found in milk and beef may be a trigger for developing rheumatoid arthritis in people who are genetically at risk, according to a new study from the University of Central Florida.

30 Jan 2018

Researchers win $6.5 million NIH grant to personalize diagnosis and treatment of psoriasis

An experienced interdisciplinary team of psoriasis and computational researchers from Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center has received a $6.5M, 5-year grant from the National Institute of Arthritis, Musculoskeletal and Skin Diseases.

29 Jan 2018

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

In the first such collaboration of its kind, an expert panel of rheumatologists and orthopedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement.

16 Jun 2017

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease. The team used sedimentation velocity analytical ultracentrifugation to investigate drug-target binding in a physiological environment and at clinically-relevant concentrations.

15 May 2017

BSR and RCGP introduce joint project to improve care for people with inflammatory arthritis

BSR and the RCGP have today launched a joint Quality Improvement project to improve care for people living with inflammatory arthritis.

10 May 2017

Researchers reveal immune machinery that goes awry to trigger neutrophilic dermatosis

A research team led by St. Jude Children's Research Hospital immunologists has revealed a previously unknown immune machinery that goes awry to trigger the inflammatory disease neutrophilic dermatosis.

18 Apr 2017

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints®, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy and patient-centered research, today announced the publication of “Raising the Voice of the Patients: A Patient’s Guide to Living with Rheumatoid Arthritis”.

25 Jan 2017

Psoriatic arthritis patients experience multiple symptoms that can make diagnosis difficult, survey reveals

Psoriatic arthritis (PsA) is an inflammatory condition closely related to and most often co-occurring with psoriasis.

16 Nov 2016

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy, and patient-centered research, today announced the forthcoming publication of “A Patient’s Guide to Living with Rheumatoid Arthritis.”

15 Nov 2016

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016

Almirall launches ‘Not Today’ story to raise awareness about psoriasis

In the framework of the World Psoriasis Day, which this year’s theme is “Breaking Barriers”, the International Federation of Psoriasis Association (IFPA) aims to raise awareness, fight prejudices and gain access to proper diagnosis for people with psoriasis.

1 Nov 2016

FDA approves new biosimilar for multiple inflammatory diseases

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.

23 Sep 2016

Penn State dermatologist clarifies common myths about psoriasis

Psoriasis is a much-misunderstood disease, often kept under wraps by sufferers who want to hide their skin lesions.

26 Aug 2016

Research finding opens door to new treatment options for inflammatory rheumatism

Enthesitis, inflammation of tendons where they attach to the bone, is a common medical problem which underlies various forms of inflammatory rheumatism.

23 Aug 2016

New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a newly developed method of evaluating the impact of different comorbidities in patients with Psoriatic Arthritis (PsA) can be used to prospectively identify those PsA patients at greater risk of hospitalisation and premature death.

10 Jun 2016

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra or Remsima).

10 Jun 2016

Review sheds new light on link between smoking habits and psoriasis

Psoriasis: Targets and Therapy has published the review "Psoriasis and smoking: links and risks". As corresponding author Professor Luigi Naldi says "The review in Psoriasis: Targets and Therapy throws new light on the relation between smoking habits and psoriasis.

1 Jun 2016

People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

In a new University of Manchester study, people with psoriatic arthritis have told researchers about the condition's deeply damaging mental effects and how healthcare services failed to prepare them for its reality.

29 Apr 2016

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.

6 Apr 2016